Want to see CODX full AI Analyst Report?
CODX Stock Chart & Stats
$1.21
-$0.06(-2.86%)
At close: 4:00 PM EDT
$1.21
-$0.06(-2.86%)
Day’s Range― - ―
52-Week Range$0.63 - $46.50
Previous Close$2.03
Volume162.41K
Average Volume (3M)341.97K
Market Cap
$4.87M
Enterprise Value$11.51M
Total Cash (Recent Filing)$3.65M
Total Debt (Recent Filing)$1.80M
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Nov 05, 2026EPS Estimate
-1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.72
Shares Outstanding7,444,378
10 Day Avg. Volume519,049
30 Day Avg. Volume341,968
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market Cap2.36
Enterprise Value/Revenue15.96
Enterprise Value/Gross Profit197.81
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$4.00Price Target Upside230.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-12.15
Revenue Forecast (FY)$552.40K
Bulls Say, Bears Say
Bulls Say
Regulatory And Clinical ProgressThe completed analytical work, large clinical enrollment and dual FDA submission advance Co-Diagnostics toward commercialization of a multiplex respiratory assay. This progress can reduce technology and regulatory uncertainty and create a foundation for recurring diagnostic revenue if clearance and market adoption follow.
Platform And International ExpansionInternational commercialization and manufacturing partnerships broaden the platform’s potential reach beyond the domestic market while supporting localized production. If execution continues, these relationships may improve market access, scalability and adoption across regions with significant infectious-disease testing needs.
Low Absolute Debt BurdenCo-Diagnostics carries modest absolute debt and manageable debt relative to its remaining equity base, so interest and principal obligations are not currently the main balance-sheet constraint. This provides more flexibility than a highly leveraged structure, although ongoing losses still weaken that cushion.
Bears Say
Collapsed Revenue And Persistent LossesThe sharp revenue contraction shows that prior demand has not translated into a durable commercial base. Large losses against minimal sales indicate the current cost structure remains poorly matched to revenue, making sustained profitability dependent on successful commercialization and substantial future growth.
Cash Burn And Financing DependenceStructured secured financing highlights limited liquidity flexibility and increases dependence on external capital to fund operations. Senior asset liens, repayment requirements and discounted conversion provisions can constrain future choices while creating dilution and execution risk if commercialization does not accelerate.
Governance And Shareholder Engagement FrictionRepeated quorum failures can delay shareholder approvals and other formal corporate actions, slowing governance processes and potentially affecting strategic or financing initiatives. The pattern also signals shareholder engagement friction at a time when the company needs coordinated support for its capital and operating plans.
Co-Diagnostics News
CODX FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was $0.63 and its highest was $46.50 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is $4.87M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 17 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Aug 13, 2026. The company reported -$1.46 earnings per share for the quarter.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -1.25.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 7,444,378 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$1.46 in its last earnings report. Following the earnings report the stock price went down -6.04%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in CODX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
CODX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.View all CODX earnings summariesCODX Stock 12 Month Forecast
Average Price Target
$4.00
▲(230.58% Upside)
Technical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Ownership Overview
1.30% Insiders
0.48% Mutual Funds
3.70% Other Institutional Investors
93.73% Public Companies and
Individual Investors